Comments
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ibandronate Sodium Injection.
It is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva Injection of Hoffmann-La Roche, Inc. Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women.
Aurobindo has also received final approval from the USFDA to manufacture and market Omeprazole Delayed-release Capsules.
It is bioequivalent and therapeutically equivalent to the reference listed drug product Prilosec Delayed-release Capsules of AstraZeneca Pharmaceuticals.
The tablets are indicated for short-term treatment of active duodenal ulcer in adults. The product has an estimated market size of $422 million for the 12 months ended June 30, 2015, according to IMS.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.